Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
March 18, 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 12, 2024 16:05 ET
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector® - - Strengthened...
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
February 29, 2024 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
February 07, 2024 08:00 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to...
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
December 14, 2023 07:05 ET
|
Clearside Biomedical, Inc.
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023 16:05 ET
|
Clearside Biomedical, Inc.
- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5...
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
November 08, 2023 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting
November 07, 2023 16:20 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
November 02, 2023 07:05 ET
|
Clearside Biomedical, Inc.
Clearside Biomedical announced that multiple oral & poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Mtg.
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
November 01, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Nov. 01, 2023 ...